PORTFOLIO NEWS Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares August 3, 2021 Read More » eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent July 22, 2021 Read More » NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration July 22, 2021 Read More » MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology July 15, 2021 Read More » Ribon Therapeutics Secures $65 Million Financing July 14, 2021 Read More » Escient Pharmaceuticals Announces Positive Results From Phase 1 Study Of EP547, An MrgprX4-Targeted Oral Therapy For Cholestatic And Uremic Pruritus July 14, 2021 Read More » Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update July 13, 2021 Read More » Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021 July 12, 2021 Read More » Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO) July 9, 2021 Read More » NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors July 7, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Tenaya Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares August 3, 2021 Read More »
eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent July 22, 2021 Read More »
NGM Announces Completion of Enrollment in Phase 2 CATALINA Study of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration July 22, 2021 Read More »
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology July 15, 2021 Read More »
Escient Pharmaceuticals Announces Positive Results From Phase 1 Study Of EP547, An MrgprX4-Targeted Oral Therapy For Cholestatic And Uremic Pruritus July 14, 2021 Read More »
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update July 13, 2021 Read More »
Tenaya Therapeutics Unveils Preclinical Research Supporting Product Candidate for Rare and Prevalent Heart Disease Indications at ESC Heart Failure 2021 July 12, 2021 Read More »
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO) July 9, 2021 Read More »
NGM Bio Announces Initiation of Phase 1/2 Clinical Study of NGM707 for the Treatment of Advanced Solid Tumors July 7, 2021 Read More »
